• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型长效聚乙二醇干扰素 alfa-2b 在健康中国受试者中的药代动力学和药效学。

Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects.

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, No. 252, Wuxing Street, Xinyi District, Taipei City, 110301, Taiwan.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, No. 252, Wuxing Street, Xinyi District, Taipei City, 110301, Taiwan.

出版信息

Adv Ther. 2021 Sep;38(9):4756-4770. doi: 10.1007/s12325-021-01863-y. Epub 2021 Jul 30.

DOI:10.1007/s12325-021-01863-y
PMID:34328630
Abstract

INTRODUCTION

Ropeginterferon alfa-2b is a novel mono-pegylated human recombinant interferon (IFN) with the addition of N-terminal proline covalently attached by a 40-kDa polyethylene (peg) moiety. The present study aimed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD) profiles and safety of the product in healthy Chinese.

METHODS

Forty subjects were enrolled and treated with a single subcutaneous injection of either 180 mcg peg-IFN alfa-2a or 90, 180, and 270 mcg ropeginterferon alfa-2b.

RESULTS

The mean T of ropeginterferon alfa-2b was 92-141 h and the elimination half-life was 78-129 h. Dose-related, non-proportional increase in ropeginterferon alfa-2b exposure was observed, which was higher than for peg-IFN alfa-2a. The PD parameters were similar between each dose level of ropeginterferon alfa-2b. The mean T of β-microglobulin ranged from 118 to 132 h after a single dose of ropeginterferon alfa-2b. The average E was 3 mcg/ml in all dose levels and the mean AUEC ranged from 1608 to 1775 h/mcg/ml. The TEAEs were comparable among each treatment group and no death nor drug-related SAE was reported.

CONCLUSION

Ropeginterferon alfa-2b is safe and well tolerated after a single subcutaneous injection up to 270 mcg in healthy Chinese.

CLINICAL TRIAL REGISTRATION

www.chinadrugtrials.org.cn , CTR20190451.

摘要

简介

罗哌干扰素 alfa-2b 是一种新型的单聚乙二醇化人重组干扰素(IFN),其 N 端脯氨酸通过 40 kDa 聚乙二醇(peg)部分共价连接。本研究旨在评估该产品在健康中国人体内的药代动力学(PK)、药效学(PD)特征和安全性。

方法

共招募 40 名受试者,分别单次皮下注射 180 mcg 聚乙二醇干扰素 alfa-2a 或 90、180 和 270 mcg 罗哌干扰素 alfa-2b。

结果

罗哌干扰素 alfa-2b 的平均 T 为 92-141 h,消除半衰期为 78-129 h。观察到罗哌干扰素 alfa-2b 暴露量呈剂量相关、非比例增加,高于聚乙二醇干扰素 alfa-2a。罗哌干扰素 alfa-2b 各剂量水平的 PD 参数相似。单次给药后,β-微球蛋白的平均 T 范围为 118-132 h。所有剂量水平的平均 E 为 3 mcg/ml,平均 AUEC 范围为 1608-1775 h/mcg/ml。各治疗组的 TEAEs 相似,无死亡或药物相关严重不良事件报告。

结论

在中国健康受试者中,单次皮下注射罗哌干扰素 alfa-2b 剂量高达 270 mcg 是安全且耐受良好的。

临床试验注册

www.chinadrugtrials.org.cn , CTR20190451。

相似文献

1
Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects.新型长效聚乙二醇干扰素 alfa-2b 在健康中国受试者中的药代动力学和药效学。
Adv Ther. 2021 Sep;38(9):4756-4770. doi: 10.1007/s12325-021-01863-y. Epub 2021 Jul 30.
2
Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.新型长效聚乙二醇干扰素 alfa-2b:I 期临床试验中的药代动力学、药效学和安全性。
Br J Clin Pharmacol. 2022 May;88(5):2396-2407. doi: 10.1111/bcp.15176. Epub 2021 Dec 28.
3
Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.单次皮下给药后,聚乙二醇化干扰素α-2b在健康日本人和高加索人受试者中的药代动力学和药效学。
Clin Drug Investig. 2021 Apr;41(4):391-404. doi: 10.1007/s40261-021-01026-5. Epub 2021 Mar 16.
4
Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.聚乙二醇干扰素α-2b治疗基因1型慢性丙型肝炎患者:药代动力学、安全性及初步疗效
JGH Open. 2021 Jul 10;5(8):929-940. doi: 10.1002/jgh3.12613. eCollection 2021 Aug.
5
Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.罗氏干扰素 alfa-2b 每两周给药一次,用于治疗基因型 2 慢性丙型肝炎患者。
J Formos Med Assoc. 2021 Mar;120(3):956-964. doi: 10.1016/j.jfma.2020.09.018. Epub 2020 Oct 16.
6
A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment.罗氏干扰素 Alfa-2b 治疗丙型肝炎的治疗剂量及其药代动力学。
J Formos Med Assoc. 2024 Jan;123(1):55-61. doi: 10.1016/j.jfma.2023.08.023. Epub 2023 Sep 2.
7
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.每 2 周使用罗匹尼罗干扰素 alfa-2b 作为新型聚乙二醇干扰素治疗慢性乙型肝炎患者。
Hepatol Int. 2020 Dec;14(6):997-1008. doi: 10.1007/s12072-020-10098-y. Epub 2020 Oct 24.
8
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.聚乙二醇干扰素α-2b对比真性红细胞增多症标准疗法(PROUD-PV和CONTINUATION-PV):一项随机、非劣效性3期试验及其扩展研究。
Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.
9
Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan.台湾地区 COVID-19 患者标签外使用罗匹尼罗干扰素 alfa-2b 的临床经验。
Adv Ther. 2022 Feb;39(2):910-922. doi: 10.1007/s12325-021-01998-y. Epub 2021 Dec 15.
10
Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects.聚乙二醇干扰素α-2b的群体药代动力学:健康白种人与中国受试者的比较
Front Pharmacol. 2021 May 28;12:673492. doi: 10.3389/fphar.2021.673492. eCollection 2021.

引用本文的文献

1
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.聚乙二醇干扰素α-2b在中国和日本真性红细胞增多症患者中的群体药代动力学-药效学及暴露-反应关系
Pharmacol Res Perspect. 2025 Jun;13(3):e70109. doi: 10.1002/prp2.70109.
2
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.PARADIGM-PV:一项随机、多中心4期研究,旨在评估聚乙二醇干扰素α-2b治疗低危或高危真性红细胞增多症患者的疗效和安全性。
Ann Hematol. 2025 Jan;104(1):335-345. doi: 10.1007/s00277-025-06185-5. Epub 2025 Jan 13.
3

本文引用的文献

1
Side effects of therapy of hepatitis C and their management.丙型肝炎治疗的副作用及其管理
Hepatology. 2002 Nov;36(5 Suppl 1):S237-44. doi: 10.1053/jhep.2002.36810.
2
The role of interferon-alpha in the treatment of myeloproliferative disorders.α干扰素在骨髓增殖性疾病治疗中的作用。
Curr Pharm Des. 1999 Dec;5(12):987-1013.
3
Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment.干扰素治疗期间干扰素、白蛋白及β2-微球蛋白的尿排泄情况。
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.
聚乙二醇干扰素α-2b治疗真性红细胞增多症的药代动力学、疗效和安全性的种族敏感性分析。
Front Pharmacol. 2024 Sep 24;15:1455979. doi: 10.3389/fphar.2024.1455979. eCollection 2024.
4
A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.一项评估聚乙二醇干扰素α-2b治疗中度新型冠状病毒肺炎(COVID-19)患者疗效和安全性的3期随机对照试验。
Infect Dis Ther. 2024 Jul;13(7):1575-1588. doi: 10.1007/s40121-024-00992-5. Epub 2024 May 21.
5
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.用聚乙二醇干扰素α-2b治疗有效管理真性红细胞增多症
J Hematol. 2024 Apr;13(1-2):12-22. doi: 10.14740/jh1245. Epub 2024 Apr 9.
6
Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results.罗氏干扰素 α-2b 和抗程序性细胞死亡蛋白 1 抗体序贯治疗抑制乙型肝炎相关肝细胞癌复发:从动物模型到 I 期临床结果。
Int J Mol Sci. 2023 Dec 28;25(1):433. doi: 10.3390/ijms25010433.
7
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.聚乙二醇干扰素α-2b的一种新给药方案高效且耐受性良好:一项针对中国真性红细胞增多症患者的2期研究结果
Exp Hematol Oncol. 2023 Jun 21;12(1):55. doi: 10.1186/s40164-023-00415-0.
8
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.聚乙二醇干扰素α-2b的一种替代给药策略可能有助于改善骨髓增殖性肿瘤的治疗结果:既往及正在进行的研究概述与未来展望
Front Oncol. 2023 Jan 19;13:1109866. doi: 10.3389/fonc.2023.1109866. eCollection 2023.
9
A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.一项验证一种创新的长效干扰素治疗慢性丙型肝炎的效力和安全性的3期临床试验。
JGH Open. 2022 Oct 10;6(11):782-791. doi: 10.1002/jgh3.12825. eCollection 2022 Nov.
10
Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.新型聚乙二醇干扰素治疗慢性病毒性肝炎。
Viruses. 2022 May 25;14(6):1128. doi: 10.3390/v14061128.
Cancer Res. 1984 Aug;44(8):3599-603.